Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

(2020) Christopher T Ritchlin et al.   LANCET

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial

(2019) Philip J. Mease et al.   Arthritis & Rheumatology

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

(2018) Philip Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

(2018) Peter Nash et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

(2018) Atul Deodhar et al.   LANCET

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

(2018) Alvin F Wells et al.   RHEUMATOLOGY

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study

(2018) Elizabeth G. Araujo et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response

(2018) Philip J. Mease et al.   Arthritis & Rheumatology

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

(2018) Philip Mease et al.   LANCET

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

(2017) Philip Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

(2017) Dafna Gladman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

(2017) Iain B McInnes et al.   RHEUMATOLOGY

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis

(2017) Arthur Kavanaugh et al.   Arthritis & Rheumatology

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers

(2016) Karin Hellgren et al.   ANNALS OF THE RHEUMATIC DISEASES

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

(2016) Christopher J Edwards et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts

(2016) Amir Haddad et al.   JOURNAL OF RHEUMATOLOGY

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study

(2016) A. Kavanaugh et al.   JOURNAL OF RHEUMATOLOGY

Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study

(2016) L. Costa et al.   JOURNAL OF RHEUMATOLOGY

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

(2016) M. Cutolo et al.   JOURNAL OF RHEUMATOLOGY

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

(2016) Désirée van der Heijde et al.   Arthritis & Rheumatology

The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

(2016) Philip J. Mease et al.   Arthritis & Rheumatology

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry

(2015) L Dreyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence and predictors for cardiovascular events in patients with psoriatic arthritis

(2015) Lihi Eder et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

(2015) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F))

(2015) Anna Moverley et al.   CLINICAL RHEUMATOLOGY

Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden

(2015) Lars Erik Kristensen et al.   JOURNAL OF RHEUMATOLOGY

Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry

(2015) D. Choquette et al.   JOURNAL OF RHEUMATOLOGY

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

(2015) A. Kavanaugh et al.   JOURNAL OF RHEUMATOLOGY

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial

(2015) Arthur Kavanaugh et al.   ARTHRITIS CARE & RESEARCH

Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study

(2014) Alexis Ogdie et al.   ANNALS OF THE RHEUMATIC DISEASES

Psoriatic arthritis treatment and the risk of herpes zoster

(2014) D Zisman et al.   ANNALS OF THE RHEUMATIC DISEASES

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

(2014) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission

(2013) Elizabeth G Araujo et al.   ANNALS OF THE RHEUMATIC DISEASES